UBS Assumes Pacific Biosciences at Neutral, Lowers Price Target of $1.35

Benzinga Newsdesk www.benzinga.com Neutral 77.2%

Neg 0% Neu 77.2% Pos 0%

UBS analyst Doug Schenkel assumes Pacific Biosciences (NASDAQ:PACB) with a Neutral rating and lowers Price Target of $1.35.